S&P Biotechnology Select Industry Index S&P Dow Jones Indices

S&P Select Industry Indices are designed to measure the performance of narrow GICS® sub-industries. The S&P Biotechnology Select Industry Index comprises stocks in the S&P Total Market Index that are classified in the GICS Biotechnology sub-industry. Please register here to receive timely updates and insights from Nasdaq Global Indexes. Tax Rate data for other ETFs in the Health & Biotech Equities ETF Database Category is presented in the following table.

The index is a modified capitalization weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical. The securities also meet other eligibility criteria determined by The NASDAQ OMX Group, Inc., including a minimum market capitalization of $200 million and an average daily trading volume of at least 100,000 shares. The index is given a semi-annual ranking review to ensure that all components are still able to meet the criteria for inclusion. work in progress formula The NASDAQ Biotechnology Index is a stock market index made up of securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either the Biotechnology or the Pharmaceutical industry.[1] A list of the 213 components of the index is published online. The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria.

NASDAQ Biotechnology Components

Holdings data for other ETFs in the Health & Biotech Equities ETF Database Category is presented in the following table. Historical return data for other ETFs in the Health & Biotech Equities ETF Database Category is presented in the following https://1investing.in/ table. ETF Database staff has allocated each ETF in the ETF database, as well as each index, to a single ‘best-fit’ ETF Database Category. Other ETFs in the Health & Biotech Equities ETF Database Category are presented in the following table.

The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. This list includes investable products traded on certain exchanges currently linked to this selection of indices. While we have tried to include all such products, we do not guarantee the completeness or accuracy of such lists. Please refer to the disclaimers here for more information about S&P Dow Jones Indices’ relationship to such third party product offerings. Access exclusive data and research, personalize your experience, and sign up to receive email updates.

Biotech Stocks Are Poised to Outperform for the Rest of 2022

Mergers were still in the doldrums, although there were several noteworthy multi-billion-dollar acquisitions; Amgen’s $27.8 billion acquisition of Horizon Therapeutics (still under review by the Federal Trade Commission) sits at the top. And the beat goes on into this year with several mega-acquisitions in the first half of the year, including the $43 billion acquisition of antibody–drug conjugate pioneer Seagen by Pfizer. More deals are anticipated as pharma adjusts to the post-Inflation Reduction Act environment, as well as to some noteworthy patent expirations. President Donald Trump is expected to nominate conservative health policy expert Dr. Scott Gottlieb to head the Food and Drug Administration, media outlets including Bloomberg, Reuters and the Wall Street Journal reported …